The use of TNF inhibitors therapy by patients with systemic rheumatic diseases significantly increases the number of incident cases of tuberculosis in this population, with an 18-time increased TB incidence in these patients when compared to the general population. The gene discussed is TNF; the disease is tuberculosis.